Updated from 3:45 p.m. EDT

Widely held health stocks sank into malaise Tuesday, and not even continued hype about the swine flu could lift them out of the red.

Shares of GlaxoSmithKline ( GSK) -- among the prized truffles in the health sector Monday because it makes Relenza, an antiviral drug that could be used to combat swine flu -- fell 3.1% to $30.58.

Pfizer ( PFE), which reported first-quarter earnings Tuesday, lowered its 2009 guidance to a range of $1.20 to $1.35 a share -- down from its previous expectations of $1.34 to $1.49 per share -- on costs related to its Wyeth ( WYE) acquisition. The company reaffirmed its adjusted full-year earnings of $1.85 to $1.95 per share. Pfizer stock fell 0.7% to $13.39.

Bristol-Myers Squibb ( BMY), meanwhile, also was in the red after reporting quarterly earnings. The company posted a 3% rise in profit based in part on sales of Plavix and Abilify, and it reaffirmed its full-year earnings guidance of $1.58 to $1.73 per share. Bristol's stock fell 4.3% to $19.65.

Johnson & Johnson ( JNJ) shares fell 0.4% to $50.65.

Merck ( MRK) fell 1.2% to $23.17.

Eli Lilly ( LLY), among the day's few winners (albeit barely) rose 0.2% to $33.20.

Also gaining was Schering-Plough ( SGP), which inched up 0.1% to $22.20.

In biotech news, investors were trying to make sense of what happened just before Dendreon ( DNDN) released its latest Provenge data. The company's stock saw double-digit gains before falling 45% to $11.81 before trading was halted in advance of the data release.

Gilead Sciences ( GILD), which co-developed flu treatment Tamiflu with Roche, was still riding high a day after getting a boost from the swine flu effect. Shares rose 0.2% to $47.60.

More from Stocks

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

What Will GM Do With Cruise -- and Is Its Stock Worth $55?

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

This Should Be Your Retirement Savings Plan When the Stock Market Crashes

This Should Be Your Retirement Savings Plan When the Stock Market Crashes